Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hanmi Pharmaceutical
Biotech
Why Roche is 'really excited' about UCN2's obesity potential
Roche licensed the UCN2 analog after seeing preclinical data that “clearly suggests” it can cut weight while preserving muscle, Fierce has learned.
James Waldron
Sep 3, 2026 10:47am
Roche pens $2.5B pact for Hanmi’s muscle-conserving obesity drug
Aug 24, 2026 4:42am
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome
Jun 1, 2026 3:52am
Aptose exits cancer pact after Hanmi buyout blocks development
May 14, 2026 6:35am
Gilead pumps up virology pipeline with drug transporter deal
Sep 29, 2025 10:35am
Aptose to pay Hanmi up to $420M for myeloid inhibitor
Nov 4, 2021 10:37am
